Tilray invests in Rose LifeScience
On December 14, Tilray (TLRY) announced that it’s investing in ROSE LifeScience—a cannabis producer in Quebec. The agreement between Tilray’s subsidiary High Park Farms and ROSE LifeScience entails an exclusive sale, distribution, supply, and marketing agreement.
How much is Tilray spending?
Tilray will spend 7.5 million Canadian dollars, which accounts for 12% in capital for ROSE LifeScience. The agreement doesn’t have a provision for warrants, options, or an additional equity acquisition of ROSE LifeScience.
Unlike other provinces in Canada, making inroads into the Quebec market comes with a different set of challenges and opportunities for cannabis producers (HMMJ) including Canopy Growth (WEED), Cronos Group (CRON), and Aurora Cannabis (ACB).
Acquiring ROSE LifeScience will be an asset to Tilray in the Quebec market. The press release said, “The investment in ROSE represents a commitment to increase supply to the Québec market and the opportunity to deliver consumers locally-grown products.”
To learn more, read Tilray Announced Its International Advisory Board.